Trigeminal Neuralgia – Surgical Management

What is trigeminal neuralgia?

Sudden, recurrent, “electric-shock” facial pain — with a recognizable cause and well-defined treatment options.

Trigeminal neuralgia is a form of neuropathic pain involving the trigeminal nerve, the primary sensory nerve of the face. It is characterized by brief but extremely intense paroxysms of pain, often described as electric shocks or stabbing sensations, typically affecting one side of the face. Episodes last from seconds to a few minutes, but may recur multiple times throughout the day, significantly impairing quality of life.

Although the pain is severe and often frightening, trigeminal neuralgia is a condition with clear diagnostic criteria and a spectrum of effective treatments, ranging from medical therapy to specialized neurosurgical interventions.

How common is it and at what ages does it occur?

Not as “rare” as often assumed. The condition most commonly presents after age 50, but may occur earlier.

The incidence of trigeminal neuralgia is estimated at several dozen cases per 100,000 people annually. It most frequently affects individuals between 50 and 70 years of age and occurs slightly more often in women than in men.

In younger patients (particularly under 40) or when symptoms are bilateral, further investigation is required to evaluate for underlying causes such as multiple sclerosis or other central nervous system disorders.

What are the hallmark symptoms? How does it feel to the patient?

Patients often describe the pain as “an electric shock to the face,” frequently triggered by everyday activities.

A typical patient reports:

• sudden, severe pain affecting one side of the face
• sensations described as “electric shocks,” “stabbing,” or “burning”
• attacks lasting seconds to one or two minutes, often recurring
• pain-free intervals between attacks

“Trigger zones” are often present — small areas on the cheek, upper lip, or inside the mouth where light touch, brushing teeth, shaving, chewing, or exposure to cold air can precipitate an attack.

Most commonly involved are the V2 (maxillary) and V3 (mandibular) branches of the trigeminal nerve. The ophthalmic branch (V1) is less frequently affected. The pain does not cross the midline; it is always confined to one side of the face.

In some patients, in addition to classic shock-like episodes, a more persistent burning or deep aching pain may be present. These “atypical” forms require experience in both diagnosis and management.

Why does it occur – what is the underlying cause?

Most commonly due to a blood vessel compressing the nerve — though other, less frequent causes exist.

In classic trigeminal neuralgia, the most common cause is vascular compression of the trigeminal nerve at its entry point into the brainstem (the root entry zone). Typically, a branch of the superior cerebellar artery (or another vessel) contacts and chronically irritates the nerve with each arterial pulsation, leading to focal demyelination. This results in abnormal transmission of pain signals to the brain.

Less commonly, trigeminal neuralgia may result from:

• multiple sclerosis (demyelinating plaques in the trigeminal pathway)
• tumors in the posterior fossa
• aneurysms or other vascular malformations
• rare inflammatory or structural lesions along the course of the nerve

For this reason, high-resolution brain MRI is a critical step before establishing a long-term treatment plan.

How is the diagnosis made?

The diagnosis is primarily clinical. The patient’s description of pain episodes is highly characteristic.

Diagnosis of trigeminal neuralgia is based largely on clinical evaluation by an experienced neurologist or neurosurgeon. Your physician will ask:

• the exact quality of the pain (electric, burning, stabbing, etc.)
• its precise facial distribution and whether it changes location
• the duration and frequency of attacks
• what triggers episodes (chewing, touch, speech, cold air)
• whether there are pain-free intervals

A focused neurologic examination is also performed to detect numbness, weakness, or other signs suggesting an alternative cause.

A brain MRI with dedicated trigeminal nerve protocols is then required to:

• exclude tumors, aneurysms, or other structural lesions
• evaluate for multiple sclerosis
• identify possible vascular contact or compression of the nerve

How is it distinguished from other causes of facial pain?

Not all facial pain is trigeminal neuralgia — accurate differential diagnosis is essential.

Numerous conditions can cause facial pain, including:

• dental disease, root infections, abscesses
• sinus disorders
• temporomandibular joint (TMJ) disorders
• atypical facial pain, headaches, migraines
• postherpetic neuralgia (after shingles)

Classic trigeminal neuralgia is distinguished by:

• paroxysmal attacks of pain
• very high intensity, described as “electric” or “stabbing”
• brief duration (seconds rather than continuous hours)
• distribution in one or two trigeminal branches (V2, V3)
• strict unilateral involvement

In younger patients or those with atypical, more continuous pain, careful evaluation is required to exclude rarer diagnoses. At Neuroknife, this diagnostic phase is handled with particular rigor, as accurate diagnosis determines the entire treatment strategy.

When is treatment necessary?

We treat the patient, not imaging findings. Our goal is pain control and restoration of quality of life.

Trigeminal neuralgia is inherently painful and often progressive. In most patients, once the diagnosis is clear and attacks interfere with daily activities, treatment is indicated — it is not a condition expected to resolve spontaneously.

Management almost always begins with medical therapy. If pain:

• remains poorly controlled despite appropriate dosing, or
• is controlled only at the cost of unacceptable side effects, or
• progressively worsens, requiring escalating medication doses,

then interventional or surgical treatment should be seriously considered.

In patients with very mild, infrequent symptoms and minimal functional impact, a conservative approach with close follow-up may be appropriate.

What are the medication options?

Medications are first-line therapy, but require careful selection, dosing, and monitoring.

First-line treatment typically involves antiepileptic medications, most commonly:

• carbamazepine
• oxcarbazepine

These agents act on sodium channels in nerve cells, reducing abnormal electrical discharges responsible for pain. Approximately 70–80% of patients initially respond.

Other medications that may be used alone or in combination include:

• gabapentin, pregabalin
• baclofen
• lamotrigine
• clonazepam in selected cases

These medications may cause side effects such as drowsiness, dizziness, balance disturbances, laboratory abnormalities, or rarely allergic reactions. Close follow-up and laboratory monitoring are therefore essential.

Before declaring medical therapy unsuccessful, at least two adequate monotherapy trials — and often combination therapy — should be attempted under specialist supervision.

When should surgical or interventional treatment be considered?

When pain persists despite optimal medication, or when medication side effects become intolerable.

Interventional treatment is strongly considered when:

• pain remains severe despite optimized medical therapy
• side effects prevent further dose escalation
• the patient wishes to avoid long-term dependence on high-dose medication
• MRI demonstrates clear vascular compression of the nerve (especially in classic trigeminal neuralgia)

The choice of procedure depends on:

• the patient’s age and overall health
• symptom duration and severity
• imaging findings (presence of neurovascular compression)
• the patient’s informed preferences

What interventional options are available?

From percutaneous rhizotomies and radiosurgery to microvascular decompression — each with a distinct profile.

The main interventional treatments for trigeminal neuralgia include:

Percutaneous rhizotomy procedures

Performed with a needle inserted through the cheek to the nerve entry point under fluoroscopic guidance, selectively weakening pain fibers:

• Radiofrequency rhizotomy — targeted thermal lesioning with the patient awake for precise localization
• Glycerol rhizotomy — injection of glycerol into Meckel’s cave under general anesthesia
• Balloon compression — brief inflation of a balloon to mechanically compress sensory fibers

These techniques often provide rapid relief, with variable durability and a trade-off of facial numbness in many patients.

Radiosurgery (e.g., Gamma Knife)

A non-invasive option delivering highly focused radiation to a small segment of the trigeminal nerve. Treatment is outpatient and incision-free.

Pain relief typically develops gradually over weeks to months and may last for years, with a relatively low risk of serious complications. Often recommended for older patients or those with elevated surgical risk.

Microvascular Decompression (MVD)

Microvascular decompression is an open but highly targeted microsurgical procedure in the posterior fossa. Through a small retrosigmoid craniotomy, the neurosurgeon:

• identifies the trigeminal nerve at its brainstem entry zone
• locates the compressing vessel
• repositions the vessel and interposes a small Teflon pad to prevent recurrent contact

In classic vascular-compression trigeminal neuralgia, MVD offers the highest rates of durable pain relief without permanent numbness, provided the patient is an appropriate candidate for general anesthesia.

What are the outcomes & risks of these procedures?

Transparent counseling: high rates of pain relief, but each method has advantages and limitations.

Interventional treatments generally provide high rates of immediate or gradual pain relief. However:

• Percutaneous rhizotomies offer rapid relief but higher recurrence rates over time, with common facial numbness.
• Radiosurgery has low procedural risk but delayed onset and potential gradual loss of effect.
• Microvascular decompression provides the highest long-term remission rates in classic trigeminal neuralgia, with minimal risk of permanent numbness, but carries standard posterior fossa surgical risks (bleeding, infection, CSF leak, rare hearing disturbance or cranial neuropathy).

At Neuroknife:

• we perform individualized risk–benefit analysis for each patient
• we provide honest discussion of success rates, potential complications, and real-world impact
• we make decisions collaboratively with the patient, respecting personal priorities

What should I expect after successful treatment?

Our goal is not only pain relief, but a safe return to daily life.

Recovery varies by procedure:

• After percutaneous rhizotomy, hospitalization is brief (often one day) with rapid return to light activity; pain often improves immediately, though some numbness may occur.
• After radiosurgery, no hospitalization is required, but improvement is gradual over months, with continued medication tapering as response develops.
• After microvascular decompression, hospitalization lasts several days; many patients experience immediate or rapid pain relief, followed by a recovery period from surgery.

The Neuroknife team is committed to helping you make informed decisions at every stage of care.

© Neuroknife — Original medical content authored by our physicians, provided exclusively for patient education and information.